HC Wainwright Reaffirms “Buy” Rating for Bio-Path (BPTH)
Bio-Path (NASDAQ:BPTH)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Monday, November 13th, MarketBeat reports. They currently have a $1.50 target price on the stock, down from their prior target price of $4.50.
Separately, ValuEngine downgraded Bio-Path from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $1.67.
Bio-Path (NASDAQ BPTH) traded down $0.01 during mid-day trading on Monday, hitting $0.20. 751,900 shares of the stock were exchanged, compared to its average volume of 970,453. Bio-Path has a 52 week low of $0.18 and a 52 week high of $1.37.
Several institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its holdings in Bio-Path by 1.7% in the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after acquiring an additional 5,172 shares during the last quarter. Sabby Management LLC raised its holdings in Bio-Path by 73.2% in the 2nd quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock valued at $462,000 after acquiring an additional 503,488 shares during the last quarter. HighTower Advisors LLC raised its holdings in Bio-Path by 0.3% in the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after acquiring an additional 4,000 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in Bio-Path by 5,474.3% in the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after acquiring an additional 1,741,978 shares during the last quarter. Hedge funds and other institutional investors own 9.36% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “HC Wainwright Reaffirms “Buy” Rating for Bio-Path (BPTH)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/31/hc-wainwright-reaffirms-buy-rating-for-bio-path-bpth.html.
Bio-Path Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.